Efficacy and safety of reduced‐dose chemotherapy plus immunotherapy in patients with lung squamous cell carcinoma: A real‐world observational study

BACKGROUND: Recently, chemotherapy plus immunotherapy has achieved remarkable efficacy in lung squamous cell carcinoma (LUSC). However, some patients, especially frail people, cannot tolerate full‐dose chemotherapy in the real world. To reduce toxicity, appropriate dose reduction in chemotherapy is...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouyang, Ganlu, Liu, Yanyang, Liu, Jiewei, Huang, Lin, Luo, Feng, Li, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557858/
https://www.ncbi.nlm.nih.gov/pubmed/37676094
http://dx.doi.org/10.1002/cam4.6478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557858/
https://www.ncbi.nlm.nih.gov/pubmed/37676094
http://dx.doi.org/10.1002/cam4.6478

Ejemplares similares